Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Oct 25, 2023
Trader Robot Strikes Again with +5.44% Weekly Gain on $ACET

Trader Robot Strikes Again with +5.44% Weekly Gain on $ACET

In the world of AI trading robots, the "Trend Trader, Popular Stocks: Price Action Trading Strategy (TA&FA)" has become a popular choice for investors. These sophisticated bots have been making waves in the financial market, recently delivering impressive results. During the previous week, these trading bots managed to secure a remarkable gain of +5.44% while actively trading ACET. In this article, we will delve into the specifics of ACET's earnings and market trends, shedding light on what's driving the success of these AI trading robots.

MACD Indicator: A Positive Omen for ACET

One of the key factors contributing to the success of the AI trading bots is the analysis of the Moving Average Convergence Divergence (MACD) indicator for ACET. On October 5, 2023, the MACD Histogram for ACET crossed above the signal line, signaling a positive trend. This is a significant technical indicator that often piques the interest of traders.

Historical data shows that when ACET's MACD turns positive, the stock tends to continue its upward trajectory. Out of 39 instances where the MACD turned positive, ACET's stock price rose in 34 of them over the following month. This historical data indicates an impressive 87% success rate for predicting an upward trend in ACET's stock price.

Earnings Report: A Mixed Bag for ACET

One critical aspect that AI trading bots consider when making trading decisions is the company's earnings. ACET reported its last earnings on August 09, which showed earnings per share (EPS) of -75 cents. This result fell short of the estimated -46 cents, highlighting a significant earnings miss.

To put this in perspective, with 153.57K shares outstanding, the current market capitalization for ACET stands at 64.60M. This earnings report will undoubtedly have an impact on the trading strategies employed by AI bots.

Dividend Dates and Their Implications

Investors often consider dividends when making trading decisions. ACET paid a quarterly dividend of $0.01 per share, with a record date of October 09, 2018, and an ex-dividend date of September 21, 2018. The ex-dividend date is an important factor to consider. If you buy a stock on or after this date, you won't receive the next dividend payment. Instead, the dividends are retained by the seller. However, if you purchase the stock before the ex-dividend date, you will receive the dividends.

Market Capitalization Insights

Understanding a company's market capitalization is crucial for investors. In the biotechnology industry, ACET's market capitalization of 64.60M places it on the lower end of the spectrum. The average market capitalization for companies in this industry is 2.19B, with a wide range of values, from 402M to 429.71B. For comparison, the highest-valued company in this group is NVO at 429.71B, while the lowest is PNEXF at 402M.

Price Trends and Volatility in the Biotechnology Industry

Market trends play a significant role in the success of AI trading bots. In the biotechnology industry, the average weekly price growth for all stocks was -3%, indicating a slight decline. The average monthly price growth was -5%, while the average quarterly price growth was -15%. These figures suggest a challenging environment for traders in this industry.

Notably, ADXN experienced the highest price growth at a staggering 1,510%, showcasing the potential for significant gains in the biotech sector. Conversely, ATHX experienced a substantial decline, with a -82% drop in its stock price, highlighting the industry's inherent volatility.

Volume: An Indicator of Trading Activity

Trading volume is a crucial indicator for traders and AI trading bots. In the biotechnology industry, the average weekly volume growth for all stocks was -25%, suggesting a decline in trading activity. On a monthly basis, the average volume growth was -6%, indicating a persistent downtrend. However, the quarterly volume growth was a notable exception, showing a significant 72% increase in trading activity.

In summary, the success of AI trading robots is often attributed to their ability to analyze a plethora of data, including technical indicators, earnings reports, market trends, and trading volumes. The positive MACD crossover for ACET, despite a recent earnings miss, suggests a potential upward trend. However, the broader trends in the biotechnology industry and trading volumes indicate a more challenging environment.

Related Ticker: ACET

Contributor

Dem Sem's AvatarDem Sem|Expert

ACET in upward trend: price may jump up because it broke its lower Bollinger Band on September 28, 2026

ACET may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 30 cases where ACET's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ACET's RSI Indicator exited the oversold zone, 26 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +12.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACET advanced for three days, in 239 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

The Aroon Indicator entered an Uptrend today. In 143 of 170 cases where ACET Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACET as a result. In 80 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for ACET turned negative on September 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 38 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

ACET moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ACET crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACET declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.495) is normal, around the industry mean (26.780). P/E Ratio (6.061) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. ACET’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACET’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.21B. The market cap for tickers in the group ranges from 58 to 133.74B. VRTX holds the highest valuation in this group at 133.74B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -5%. For the same Industry, the average monthly price growth was -16%, and the average quarterly price growth was -5%. LONA experienced the highest price growth at 64%, while AVBP experienced the biggest fall at -49%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -2%. For the same stocks of the Industry, the average monthly volume growth was 61% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: 1 (-100 ... +100)
View a ticker or compare two or three
ACET
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a distributor of pharmaceutical intermediate ingrediants and other industrial chemicals

Industry Biotechnology

Industry
Medical Distributors
Address
131 Dartmouth Street
Phone
+1 650 503-9095
Employees
102
Web
https://www.adicetbio.com
Interact to see
Advertisement
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
I've always appreciated how Mastercard (MA) maintains a commanding position in the global payments industry, processing transactions across 3.4 billion cards at 150 million merchant locations worldwide. The network effects here create a formidable moat—increased adoption by issuers, acquirers, and consumers just reinforces its dominance. What stands out to me is how Mastercard is evolving beyond a pure processor into a services-first platform. Value-added services (VAS)—covering cybersecurity, data analytics, and consulting—are now approaching 40% of revenues and growing at double the rate of traditional payments.
MU shares are declining approximately -6.00% in premarket trading on April 2, 2026, pulling back to roughly $353.70 from the prior session's close of $376.27. The primary catalyst is a sweeping new round of tariff announcements from the Trump administration, dubbed by markets as "Liberation Day 2.0," which has sparked a broad risk-off selloff across technology and semiconductor stocks
Shares of Robinhood Markets are down approximately 6.15% in Thursday's intraday session, trading around $65.80 after closing at $70.11 on April 1, 2026. Wolfe Research delivered a sharp blow by cutting its price target on HOOD by 30%, citing persistent weakness in crypto trading volumes as a core drag on revenue.
Shares of Iridium Communications (IRDM) surged approximately +11.00% in Thursday's session, rising from a prior close of $28.52 to an intraday high near $31.76. A broad-based equity market rally drove significant gains across communication and satellite sector stocks, as investor sentiment sharply reversed after days of macro-driven selling pressure tied to tariff fears.
AirSculpt Technologies, Inc. (AIRS) stands out as a leading provider of minimally invasive body contouring procedures through its Elite Body Sculpture brand. The company specializes in proprietary AirSculpt treatments that remove fat and tighten skin without general anesthesia. These include options like AirSculpt+, AirSculpt Smooth for cellulite reduction, and specialized fat transfer procedures such as Power BBL for Brazilian butt lifts, Up a Cup for breast enhancement, and Hip Flip for hourglass contouring. Based in Miami Beach, Florida, and founded in 2012, AIRS operates centers across the United States, Canada, and the United Kingdom.
ASRT stock surged +66% over the past 30 days, driven by strong Q4 2025 earnings beat and optimistic 2026 guidance highlighting Rolvedon growth. Over the past quarter, the stock rose +117%, fueled by improving gross margins, stable product demand, and analyst price target increases.
I've been following Advantage Solutions Inc. (ADV)closely as a key player in outsourced sales, marketing, merchandising, sampling, and retailer support services for consumer packaged goods (CPG) manufacturers and retailers across North America, Asia Pacific, and Europe. The company operates through three segments: Branded Services, Experiential Services, and Retailer Services. Its focus remains on optimizing in-store execution, boosting consumer engagement, and strengthening retail partnerships.
NCS Multistage Holdings, Inc. (NCSM) stands out as a leading provider of highly engineered products and support services that optimize oil and natural gas well construction, completions, and field development strategies. The company operates primarily in the United States, Canada, and internationally, with a focus on fracturing systems, enhanced oil recovery, well construction products, and tracer diagnostics.
MGNX stock surged +53% over the last 30 days, driven primarily by a positive Q4 earnings surprise and analyst upgrades. Over the past quarter, the stock rose +80%, reflecting recovery from early-year lows amid biotech sector volatility.
PENG shares are surging approximately +16% in today's session, trading around $20.42, up from a prior close of $17.60 The primary catalyst is a Q2 fiscal 2026 earnings beat, with non-GAAP EPS of $0.52 surpassing the consensus estimate of $0.43 — a ~21% upside earnings surprise.
CareCloud, Inc. (CCLD) delivers cloud-based software-as-a-service (SaaS) solutions, revenue cycle management (RCM), and electronic health records (EHR) tailored for medical practices. The company's model centers on subscription platforms that handle practice management, patient engagement, and billing, with AI-driven tools adding efficiency.
Intellicheck, Inc. (IDN) focuses on on-demand digital identity validation solutions tailored for know your customer (KYC), fraud prevention, and age verification across North America. The company's business centers on software-as-a-service (SaaS) products such as IDN-Mobile, IDN-Portal, and IDN-Direct, which verify both digital and physical identities for industries like financial services, fintech, buy-now-pay-later (BNPL) providers, e-commerce, retail, and government agencies. In the competitive landscape of identity management software, Intellicheck occupies a solid niche with its reliable offerings, especially as fraud risks continue to escalate. From what I see, the recent profitability and SaaS revenue growth provide a strong foundation for the stock's performance, highlighting scalable potential in a market with clear demand.